Gilead Sciences, Inc.

Patrick J Salvo

Seung H Lee

Jayaraman Chandrasekhar

Jeff A Zablocki

Gary Bruce Phillips

Scott A Mitchell

Rao V Kalla

Thao Perry

Musong Kim

Suet Chung Yeung

Julian Andrew Codelli

Mark J Bartlett

Jennifer R Lo

Joshua J Van Veldhuizen

Gayatri Balan

Jennifer Alissa Loyer-Drew

John H Conway

Jennifer Leigh Cosman

Sundaramoorthi Swaminathan

Zachary A Kasun

Kevin S Currie

Jennifer Anne Treiberg

Leena Patel

Stephane Perreault

Yasamin Moazami

Jennifer L Cosman Ellis

Jesse M Jacobsen

Stephen D Holmbo

Heath A Weaver

Jonah J Chang

David L Kukla

Thomas J Paul

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

PARP7 inhibitors

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted 6-azabenzimidazole compounds

Growing community of inventors

Burien, WA, United States of America

Patrick J Salvo